Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
Ella Daly(Janssen (Belgium)), Jaskaran Singh(Neurocrine Biosciences (United States)), István Bitter(Semmelweis University), Wayne C. Drevets(Johnson & Johnson (United States)), Adam Janik(Janssen (United States)), David Hough(Janssen (Belgium)), Andrea Fagiolini(University of Siena), Patricio Molero(Clinica Universidad de Navarra), Wiesław Jerzy Cubała(Gdańsk Medical University), A. Duca(Janssen (Belgium)), Madhukar H. Trivedi(Southwestern Medical Center), John Zajecka(Psychiatric Medicine Associates), Ilona Divacka, Honglan Li(Renji Hospital), Michael E. Thase(Veterans Health Administration), Pilar Lim(Janssen (Belgium)), Xiang Li(Janssen (United States)), Yun Zhang(Janssen (United States)), Richard C. Shelton(University of Alabama at Birmingham), Husseini K. Manji(National Institutes of Health), Andrew Winokur, Rosanne Lane(Janssen (Belgium)), Pierre Blier(Université du Québec à Rimouski)
Cited by 780
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
Subgenual prefrontal cortex abnormalities in mood disorders
|Nature|1997|2.7k
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression
|Brain Structure and Function|2008|2.2k
Common variants conferring risk of schizophrenia
|Nature|2009|1.7k
Neurocircuitry of Mood Disorders
|Neuropsychopharmacology|2009|1.6k